Results 21 to 30 of about 3,384,133 (256)
ACS Medicinal Chemistry Letters, 2020 Since the histone modifying enzymes EZH2 and HDACs control a number of epigenetic-dependent carcinogenic pathways, we designed the first-in-class dual EZH2/HDAC inhibitor 5 displaying (sub)micromolar inhibition against both targets.
Annalisa Romanelli +14 more
semanticscholar +1 more source
Toll-like signaling and the cytokine IL-6 regulate histone deacetylase dependent neuronal survival. [PDF]
PLoS ONE, 2012 Histone deacetylase (HDAC) proteins have a role in promoting neuronal survival in vitro, but the mechanism underlying this function has not been identified. Here we provide evidence that components of the neuronal microenvironment, including non-neuronal
Nicole Forgione, Vincent Tropepe
doaj +1 more source
Class IIa HDAC inhibitor TMP195 alleviates lipopolysaccharide-induced acute kidney injury.
AJP - Renal Physiology, 2020 Sepsis-induced acute kidney injury (SA-AKI) is associated with high mortality rates, but clinicians lack effective treatments except supportive care or renal replacement therapies.
Wei Zhang, G. Bayliss, S. Zhuang
semanticscholar +1 more source
Cells, 2021 Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with a dismal prognosis. Here, we show how an inhibition of de novo dNTP synthesis by the ribonucleotide reductase (RNR) inhibitor hydroxyurea and an inhibition of epigenetic ...
Alexandra Nguyen +5 more
doaj +1 more source
Biological Research, 2020 Background Histone deacetylase (HDAC) inhibitors are promising anticancer drugs but their effect on tumor treatment has been disappointing mainly due to the acquisition of HDAC inhibitor resistance.
Won Chan Hwang +5 more
doaj +1 more source
Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts
Pharmaceuticals, 2020 The survival rate among children with relapsed neuroblastomas continues to be poor, and thus new therapeutic approaches identified by reliable preclinical drug testing models are urgently needed.
Jagoda K. Wrobel +12 more
semanticscholar +1 more source
Underlying anti-cancer mechanisms of histone deacetylase (HDAC) inhibitors in tamoxifen-resistant breast cancer cells [PDF]
Iranian Journal of Basic Medical SciencesObjective(s): Breast cancer is an important women’s malignancy with high cancer-related deaths worldwide. Drug resistance lowers the treatment efficacy in this malignancy. This study aimed to explore the underlying mechanisms of histone deacetylase (HDAC)
Lingyan Wang, Yukai Xu, Chunhui Gao
doaj +1 more source
Valeric Acid Suppresses Liver Cancer Development by Acting as a Novel HDAC Inhibitor
Molecular Therapy: Oncolytics, 2020 Liver cancer is the fastest growing cause of cancer deaths in the United States due to its aggressiveness and lack of effective therapies. The current preclinical study examines valeric acid (pentanoic acid [C5H10O2]), one of the main compounds of ...
R. Han, O. Nusbaum, Xinyi Chen, Yong Zhu
semanticscholar +1 more source
BMC Cancer, 2023 Background This study sought to compare the benefits and safety of agents including Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors, and histone deacetylase (HDAC ...
Danyang Ji +7 more
doaj +1 more source
EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma. [PDF]
Cell Death DisT-cell lymphoma (TCL) is a rare subtype of non-Hodgkin lymphoma (NHL) that is associated with a poor prognosis. Although HDAC inhibitors have been approved for TCL treatment for several years, their expected therapeutic efficacy remains unmet in some ...
Wu J +11 more
europepmc +2 more sources